Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Operating Leases (2020 - 2025)

Historic Operating Leases for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $13.7 million.

  • Apellis Pharmaceuticals' Operating Leases rose 1988.43% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year increase of 1988.43%. This contributed to the annual value of $10.2 million for FY2024, which is 1093.94% down from last year.
  • Apellis Pharmaceuticals' Operating Leases amounted to $13.7 million in Q3 2025, which was up 1988.43% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Operating Leases registered a high of $19.9 million during Q1 2021, and its lowest value of $8.3 million during Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' median Operating Leases value was $13.2 million (recorded in 2023), while the average stood at $13.6 million.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 7815.56% in 2021, then plummeted by 2882.84% in 2023.
  • Apellis Pharmaceuticals' Operating Leases (Quarter) stood at $17.1 million in 2021, then fell by 15.98% to $14.4 million in 2022, then decreased by 20.19% to $11.5 million in 2023, then decreased by 10.94% to $10.2 million in 2024, then surged by 34.1% to $13.7 million in 2025.
  • Its Operating Leases stands at $13.7 million for Q3 2025, versus $8.3 million for Q2 2025 and $9.2 million for Q1 2025.